A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two vaginal microbicide formulations containing either Darunavir, or Dapivirine and Darunavir

Trial Profile

A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two vaginal microbicide formulations containing either Darunavir, or Dapivirine and Darunavir

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Dapivirine (Primary) ; Darunavir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms DAPIDAR v2.0
  • Most Recent Events

    • 01 Jul 2015 Accrual to date is 104% according to United Kingdom Clinical Research Network record
    • 28 May 2015 Accrual to date is 95% according to United Kingdom Clinical Research Network record
    • 14 May 2015 Accrual to date is 50% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top